Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne announces additional one-year data from ACHIEVE study
- Dyne Therapeutics Elects Brian Posner to Board
- Dyne Therapeutics receives orphan drug designation in Japan for DYNE-251 in DMD
- Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz
- Video: RH, Wayfair slip after Trump furniture tariff probe threat